Foresight Diagnostics lab (courtesy Foresight)

Fore­sight Di­ag­nos­tic­s' ap­proach for the ear­li­er de­tec­tion of can­cer re­cur­rence pulls in near­ly $59M

In a crowd­ed field of can­cer di­ag­nos­tics com­pa­nies look­ing to de­tect re­laps­es ear­li­er, Fore­sight Di­ag­nos­tics thinks it has a more sen­si­tive ap­proach. On Thurs­day, it re­ceived more than $58 mil­lion to test the the­o­ry.

Even af­ter suc­cess­ful can­cer treat­ment, reg­u­lar imag­ing can be a source of anx­i­ety for pa­tients — and a clear scan doesn’t nec­es­sar­i­ly mean a pa­tient won’t re­lapse lat­er on.

“I work with a num­ber of physi­cians and they re­cur­rent­ly say what they hate the most is telling a pa­tient, ‘As far as I can tell you’re cured, but the sta­tis­tics tell us that over the next two years you have X per­cent chance of re­lapse,’” Fore­sight CEO and co-founder Jake Chabon said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.